Table 3.
Dosimetry comparison of the resulting [18F]fluciclovine PET-MRI directed nodal boost plans compared with the original treatment plan
| Structure | Dosimetric parameter | Case 1 |
Case 2 |
Case 3 |
Case 4 |
||||
|---|---|---|---|---|---|---|---|---|---|
| Original plan | PET-MRI–directed LN boost plan | Original plan | PET-MRI–directed LN boost plan | Original plan | PET-MRI–directed LN boost plan | Original plan | PET-MRI–directed LN boost plan | ||
| PTVP+SV | V70 Gy[%] | 90.9% | 92% | 94.6% | 95% | 95% | 95% | 95% | 98.2% |
| Maximum dose | 76.4 Gy | 76.9 Gy | 76.2 Gy | 75.9 Gy | 74.2 Gy | 75.6 Gy | 75.9 Gy | 76.5 Gy | |
| PTVLN BOOST | V60.2 Gy[%] | - | 79.4% | - | 92.6% | 95.7% | 93.3% | - | 90.1% |
| Maximum dose | - | 67.4 Gy | - | 67.0 Gy | 63.1 Gy | 65.7 Gy | - | 65.8 Gy | |
| PTVeLN | V50.4 Gy[%] | 96.8% | 92% | 93.5% | 95.6% | 94.1% | 97.2% | 92.2% | 93.2% |
| Rectum | V70 Gy[cc] | 2.8 cm3 | 3.7 cm3 | 4.8 cm3 | 2.1 cm3 | 2.8 cm3 | 1.6 cm3 | 2.6 cm3 | 3.8 cm3 |
| V60 Gy[%] | 12.7% | 13.6% | 6% | 8.9% | 7.0% | 8.5% | 12% | 13.2% | |
| V50 Gy[%] | 22.4% | 24.8% | 23.2% | 30.2% | 14.3% | 18.6% | 23.2% | 27% | |
| Small bowel | Maximum dose | 55.6 Gy | 54.9 Gy | 53.8 Gy | 56.1 Gy | 57.6 Gy | 57.0 Gy | 53.6 Gy | 57.9 Gy |
| V54 Gy[cc] | 1.3 cm3 | 0.5 cm3 | 0 cm3 | 8.2 cm3 | 0.5 cm3 | 0.5 cm3 | 0 cm3 | 0.7 cm3 | |
| V45 Gy[cc] | 329 cm3 | 344 cm3 | 97.5 cm3 | 147.9 cm3 | 275.3 cm3 | 389.8 cm3 | 199.7 cm3 | 226.5 cm3 | |
| Bladder | V60 Gy[%] | 12.3% | 13.9% | 13.5% | 17.7% | 9.5% | 9.7% | 7% | 10.2% |
| V40 Gy[%] | 45.1% | 61.3% | 44.9% | 58.7% | 46.5% | 39.2% | 43.1% | 53.8% | |
| Femoral heads | V50 Gy[%] | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Abbreviations: CTV = clinical target volume; LN = lymph node; MRI = magnetic resonance imaging; P + SV = prostate and seminal vesicles; PET = positron emission tomography; PTV = planning target volume.